PCN70 Cost & Resource Utilization of Cervical Cancer in British Columbia  by Ferreira, Z.J. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A79
and common comorbid conditions included diabetes (27.3%), tumor (23.6%) and 
moderate or severe renal disease (21.2%). Simvastatin (7.3%), lisinopril (5.9%) and 
hydrocodone bitartrate/acetaminophen (5.1%) were the most frequently prescribed 
medications. During the follow-up period, PC patients had evidence of the follow-
ing health care utilizations: Medicare carrier (98.0%), Durable Medical Equipment 
(DME, 32.1%), Home Health Agency (HHA, 12.1%), outpatient visits (75.9%) and inpa-
tient hospital (29.5%), Skilled Nursing Facility (SNF, 7.2%) and hospice admissions 
(5.4%) and prescription drug (part D event) claims (43.7%). PC patients incurred 
higher Medicare carrier ($6,330), DME ($328), HHA ($647), outpatient ($19,041), 
inpatient ($5,814), SNF ($1,229), hospice ($475), pharmacy ($1,144) and total costs 
($35,008). ConClusions: Patients who were enrolled in Medicare and diagnosed 
with PC had high utilization of Carrier and outpatient services, as well as frequent 
comorbid conditions, resulting in considerable health care expenditures.
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objeCtives: In previous studies in chronic lymphocytic leukemia (CLL), adverse 
events (AEs) associated with commonly used therapies have primarily consisted 
of infusion reaction, myelotoxicity, and infection. This study estimated the cost of 
specific AEs per course of therapy associated with commonly used first-line treat-
ment regimens for CLL in the United States. Methods: This retrospective claims 
data analysis used Truven Health Analytics MarketScan® commercial and supple-
mental Medicare databases from January 2005 through August 2012. Eligible patients 
were ≥ 18 years, had a diagnosis of CLL, and continuous enrollment for ≥ 6 months 
prior to diagnosis. All patients received ≥ 1 dose of one of the following 5 regimens: 
fludarabine, cyclophosphamide, and rituximab (FCR); bendamustine plus rituximab 
(BR); chlorambucil, fludarabine plus rituximab (FR); or rituximab. AEs were identified 
from ICD-9-CM codes that either explicitly described the event of interest or that 
described interventions that were specific to the AE. Costs related to each AE were 
summed from diagnosis to the end of initial therapy. Drug costs of CLL therapies 
were excluded. Adjusted costs were estimated using a propensity-weighted general-
ized linear model (GLM), which controlled for differences in baseline characteristics 
across treatment groups. Results: Of 2,035 patients, 497 received FCR, 130 received 
BR, 449 received chlorambucil, 297 received FR, and 662 received rituximab. Mean 
age was 69.5 years (SD: 12.4) and 64% were male. Comorbidities included diabetes 
(19%), COPD (16%), and cardiovascular (14%) disease. AE results (frequency; adjusted 
cost; and 95% CI, respectively) were as follows: infusion reaction (40%; $4482; $4141-
$4862), anemia (35%; $8894; $8267-$9586), infection (26%; $7163; $6648-$7733), dysp-
nea (9%; $859; $751-$989), neutropenia (8%; $5406; $4629-$6367), febrile neutropenia 
(5%; $17,274; $14,374-$21,010), thrombocytopenia (2%; $12,621; $8933-$18,651), and 
leukopenia (1%; $1720; $1218-$2539). ConClusions: Infusion reaction, myelotoxic-
ity, and infection have substantial economic costs in CLL, which may be reduced by 
improved patient management.
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objeCtives: To collect health care resource utilization (HCRU) in the manage-
ment of chronic lymphocytic leukemia (CLL) patients who have relapsed/refrac-
tory disease, and had at least one previous chemotherapy treatment. Methods: 
A retrospective, longitudinal, cohort study design is being used involving three 
cancer centres in Ontario, Canada. A convenience sample of 90 CLL patients was 
selected with inclusion criteria of adult age at diagnosis, date of diagnosis between 
January 1, 2006 to 2012, relapsed/refractory disease that required at least one previ-
ous therapy, and minimum of one oncology visit. Demographics and HCRU data were 
collected with descriptive statistics to be presented. Costs are in 2013 Canadian dol-
lars. Results: At the Juravinski Cancer Centre (Hamilton, Ontario), 30 CLL patients 
met the study inclusion criteria. 22 were male with the mean age at diagnosis being 
65.2 years (range 41-86 years). 43% (13/30) of the interim cohort had genetic test-
ing. 73.3% of patients (22/30) received fludarabine-based chemotherapy as first-line 
treatment. 13.6% (3/22) were re-treated with fludarabine as second-line treatment. 
26.7% of patients (8/30) received chlorambucil as first-line treatment. Of those, 2 
patients were re-treated with chlorambucil as second-line treatment, 4 received 
fludarabine-based chemotherapy, and 2 did not receive further treatment. 40% of 
patients (12/30) were given rituximab. 90% of patients who needed other medica-
tions utilized a mean number of 6.0 (0-15) drugs. Half of the cohort visited the emer-
gency department a total of 19 times and experienced 25 adverse events. The total 
cost of diagnostic tests/procedures was $17,502, $28,895 for hospitalizations, and 
$49,794 for specialist visits. ConClusions: Preliminary results from one cancer 
centre indicate substantial HCRU associated with CLL management. The authors 
plan to complete data extraction at the two remaining cancer centres in order to 
determine HCRU and cost results for the full cohort.
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years, 51% female, 97% commercially-insured). Unadjusted 1-year post-failure costs 
increased by LOT for total health care (1L:$78,667, 2L:$99,624, 3L:$181,029) and medi-
cal services (i.e., non-pharmacy) (1L:$35,578, 2L:$51,078, 3L:$146,768), as did medical 
costs as a proportion of total costs (1L:45%, 2L:51%, 3L:81%). In adjusted analyses, 
compared to 1L, 2L failures had: 45% more ambulatory visits (mean 31 vs. 21, 95% CI 
on RR 1.26-1.66), 75% higher risk of hospitalization (33% vs. 23% hospitalized, 95% 
CI 1.16-2.64), 38% higher total costs (95% CI 1.14-1.68), and 73% higher medical costs 
(95% CI 1.31-2.29). Medical costs comprised a greater proportion of total costs in 2L 
vs. 1L (55% vs. 44%); pharmacy costs did not increase significantly. ConClusions: 
The burden of TKI treatment failure increases by LOT, due to increased MRU and 
associated costs. More efficacious treatment used in early therapy lines may reduce 
downstream costs by preventing treatment failure.
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objeCtives: In recent years, breast cancer remains the leading cause of death 
in women worldwide. Evaluating the economic burden of breast cancer is very 
important due to long-term treatment with expensive drugs and medical services. 
In Vietnam related studies has not been conducted until now. This is also the aim of 
this study. Methods: The cost of breast cancer has been evaluated using pharma-
coeconomic method “cost of illness” by following formula: COI = DC + IC in which: 
COI - cost of illness, DC- direct cost, IC- indirect cost A tree-decision model has been 
developed to evaluate the cost of different stages of breast cancer. This analysis was 
conducted based on the perspective of health insurance companies, therefore only 
direct medical costs were evaluated. The price of drugs and medical services have 
been averaged from the price-list of some major hospitals in Vietnam. The cost of 
disease for the whole society of Vietnam has been evaluated based on epidemiologi-
cal data in Vietnam in 2013. Results: The average cost of treatment per year of 
breast cancer in stage 0- I, II, III, IV accounts for 33,166,886; 287,057,068; 325,116,474 
and 153,352,776 VND, respectively. In the structure of average cost with the increas-
ing in severity of disease, the percentage of drug costs increase (from 28.7% in stage 
0-I to 95.1% in stage 4) and the percentage of medical services decrease (from 71.3% 
in stage 0-I to 4.9% in stage 4). The cost of breast cancer for the whole society of 
Vietnam resulted in around 6,633 billion VND. ConClusions: The cost of breast 
cancer increases following the severity level of disease with the increasing percent-
age of drugs costs and reducing percentage medical services costs. The high cost of 
breast cancer for the whole society of Vietnam needs to be concerned to conduct 
the relevant health care policies.
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objeCtives: Evaluate the economic burden of non-small cell lung cancer (NSCLC) 
in Vietnam. Methods: Economic burden analysis has been conducted, following 
which the economic burden of NSCLC for the whole society of Vietnam has been 
evaluated by following formulas: C = ∑Pi x COIi in which, C: economic burden of 
NSCLC in Vietnam; Pi: number of patients in stage i of NSCLC in Vietnam, COIi: cost 
of NSCLC in stage i The analysis has been conducted based on the perspective of 
health insurance companies, therefore only medical direct cost has been evaluated. 
The cost of drugs and medical services has been averaged from the relevant drugs 
and medical services of some major hospitals in Vietnam. The number of patients in 
every stage of NSCLC has been retrieved from epidemiological database of Vietnam in 
2010. The model has been developed to evaluate the economic burden of NSCLC and 
also further adapt the changes of price and epidemiological data over years. Results: 
The economic burden of NSCLC for the whole society of Vietnam is over 3,517 billion 
VND. In the structure of economic burden of NSCLC, the economic burden for drugs 
consists of 73.9% (2,600 billion VND), which is around 3 times higher than economic 
burden for medical services (900 billion VND). Comparing the economic burden of 
NSCLC by stages, it has been found that the economic burden of NSCLC increases 
with the increasing in the severity of disease. However stage III with the less severity 
than stage IV has the highest economic burden with the amount of 2,490 billion VND 
due to the high cost of treatment and high number of patients. ConClusions: The 
high economic burden of NCSLC should be considered to conduct the relevant health 
care policies, especially with high-cost drugs and patients in late stages of disease.
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objeCtives: To examine the economic burden and health care utilizations of U.S. 
Medicare patients diagnosed with prostate cancer (PC). Methods: A retrospec-
tive analysis was conducted using national Medicare claims data (01JAN2008-
31DEC2010). Medicare beneficiaries diagnosed with PC were identified using 
International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) 
diagnosis code 185.xx, and the initial diagnosis date designated as the index date. 
Eligible patients were required to have 1 year continuous enrollment pre- and post-
index date. Charlson Comorbidity Index (CCI) score and baseline comorbid condi-
tions were examined for the baseline period. Prescribed medications were captured 
within 60 days post-index date. Health care utilization and costs were measured 
for the follow-up period, and costs were adjusted to 2010 U.S. dollars. Results: 
A total of 21,616 PC patients were identified, of which 99.2% were male and 84.4% 
Caucasian. PC patients enrolled in Medicare had a mean age at 76.1 years and more 
often resided in the Southern U.S. region (37.7%). The baseline CCI score was 1.76, 
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health outcome estimates, findings have important implications for health care 
resource spending and to assess the cost-effectiveness of deviated first line treat-
ment practices that have emerged in the treatment of advanced ovarian cancer 
patients.
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objeCtives: The aim of this study is to determine direct medical costs of treating 
patients with prostate cancer from the perspective of a Brazilian HMO. Methods: 
An administrative database containing inpatient and outpatient claims of Unimed 
São Jose do Rio Preto, a HMO in São Paulo state with 131,064 beneficiaries, was 
reviewed from Jan/2004 to Dec/2013. Eligibility criteria were patients with a medical 
claim associated with prostate cancer (ICD-10 code C61) from Jun/2012 to Dec/2012, 
with more than 30-days of follow-up data. Diagnosis date for these patients were 
ascertained and they were followed until death or loss of follow-up, whichever 
comes first. Outcome was direct medical costs (DMC), calculated as the sum of the 
medical claims for each patient included in the analysis. DMC-per-year associated 
with prostate cancer was calculated and stratified by treatment choice (wait-and-
see, local therapy, androgen deprivation, chemotherapy). Results: 312 patients 
met eligibility criteria, with a median follow-up of 2.94 years. Total DMC in this 
population was R$ 4,247,664.42, from which R$ 1,675,255.31 (39.4%) are related to 
diagnostic exams, R$ 792,795.52 (18.7%) to hospitalizations, R$ 615,164.85 (14.5%) 
to radiotherapy, R$ 333,388.04 (7.8%) to chemotherapy and R$ 831,060.70 (19.6%) to 
other outpatient costs. A total of 143 patients started treatment as “wait-and-see” 
with average DMC-per-year related to prostate cancer of R$ 432.44/year; for patients 
starting local therapy, there were 162 patients with average DMC-per-year of R$ 
4,640.95/year; the androgen deprivation group had 19 patients with average DMC-
per-year of R$ 5.850,15/year and 4 patients started chemotherapy with an average 
DMC-per-year of R$ 33.773,22/year. ConClusions: Patients with prostate cancer 
represent a significant economic burden to private payers, escalating as disease 
progresses. Patients starting chemotherapy may cost per year approximately 6 times 
the cost of patients in early stages of the disease.
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objeCtives: This study estimated the per-event cost and economic burden 
associated with managing the most common and/or severe AEs associated with 
3 common treatment categories (chemotherapy [CT], targeted therapy [TT], and 
immunotherapy [IT]) for MM in Germany from the statutory health insurance (SHI) 
system perspective. Methods: A literature review was conducted to evaluate the 
incidence and types of AEs associated with the 3 treatment categories. A total of 
29 AEs (CT:11; TT:11; and IT:7), all-severity grades (Gr) occurring in > 20% or Gr 3/4 
occurring in > 5%, were selected. Medical resource use related to the management 
of AEs was assessed by conducting 2 blinded Delphi panel cycles with 9 clinicians. 
Published unit costs were used to estimate the costs per AE and then combined with 
AE incidence (assuming 1 occurrence/patient/cycle), treatment usage, and 1-year 
prevalence of MM (1165 cases) to estimate the treatment burden in Germany for a 
single AE occurrence. Results: The most cost-intensive AEs were all Gr 3/4. For CT, 
the most cost-intensive AEs were neutropenia/leukopenia and thrombocytopenia, 
representing a mean cost per patient of € 1744 and € 1095, respectively. For TT, AEs 
were rash and squamous cell carcinoma (SCC), with a mean cost of € 392 and € 323, 
respectively. For IT, AEs were colitis and diarrhea, with a mean cost of € 1444 and 
€ 1274, respectively. The top 5 AEs across all 3 treatment categories contributing most 
to the burden were all Gr 3/4 and included neutropenia/leukopenia (mean total cost 
of € 110,627), colitis (€ 40,534), diarrhea (€ 37,874), SCC (€ 26,237), and immune-related 
hypophysitis (€ 23,375). ConClusions: Substantial costs in the management of 
AEs are associated with MM therapies in Germany. The overall burden is likely to 
be underestimated since it does not account for AE recurrence.
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objeCtives: To examine AE rates and associated costs among mCRC patients 
treated with bevacizumab (BV) or cetuximab (CET). Methods: Using a large 
national US claims database from 1/2008-3/2012, patients with mCRC were identi-
fied (≥ 2 claims for colon or rectal cancer and metastatic disease), with enrollment 
in the health plan for ≥ 6m before and after the 1st metastatic claim date. Patients 
received BV or CET during 1st line (LOT1) and/or 2ndline (LOT2) therapy. LOT2 was 
defined as addition of any new agent ≥ 28d after start of LOT1. AEs, identified with 
ICD-9 codes on health care claims, were assessed from start of 1st targeted therapy 
in LOT1 or LOT2 to the last targeted therapy date+28d or a new LOT. Incident Rate 
Ratios (IRR) were calculated for each AE (incidence rate for CET/incidence rate for 
BV). Multivariate regression analyses assessed medical costs. Results: In LOT1, 
there were 1,255 BV and 119 CET patients; in LOT2, 671 BV and 157 CET patients. The 
CET cohort had higher incidence rates (IRR> 1; p< 0.05) in LOT1 for: dermatologic 
events (IRR= 8.67), GI (IRR= 1.38), DVT (IRR= 2.58), metabolism (IRR= 2.11), hemorrhage 
(IRR= 2.32) and infusion reactions (IRR= 1.81). In LOT2, the CET cohort had higher 
rates (p< 0.05) for: dermatologic (IRR= 9.28), GI (IRR= 1.36), DVT (IRR= 1.75), metabo-
lism (IRR= 1.75), infusion reactions (IRR= 1.54), hemorrhage (IRR= 2.32); and Sepsis 
objeCtives: To assess health care resource utilization and cost of cervical can-
cer from the perspective of British Columbia’s health care system. Methods: 
Retrospective observational data on women diagnosed with cervical cancer between 
2004 and 2009 was utilized to calculate patient-level resource utilization from diag-
nosis to death or 5-year discharge. Domains of resource use included hospitaliza-
tion, chemotherapy, radiotherapy, brachytherapy, medically necessary services such 
as laboratory, physician and diagnostics billed under B.C.’s Medical Services Plan and 
medication dispensed under B.C.’s Pharmacare program. Unit costs were applied to 
health care resources, producing per-patient costs. Relevant costs, presented in 2012 
CDN dollars, were further separated by chemotherapy protocol, stage at diagnosis, 
screening history, progression date and age. Results: The average cost of treating 
cervical cancer in B.C. was $32 023, (95% CI: $29 785 - $34 260). Hospital costs were 
the largest proportion of cost at a mean proportion of 37.8% (95% CI: 35.8, 39.8) of 
total cost. Mean length of inpatient hospital visits was 11.2 days, with 2 outpatient 
hospital visits per patient. Costs were also calculated by relevant clinical subgroups, 
including progression, age, stage, screening history and treatment protocol on cost 
and resource utilization. ConClusions: Cervical cancer resource utilization and 
costs are substantial in B.C.’s health care system. Such data is necessary for decision 
makers in designing and implementing screening and disease management policy. 
Results will provide inputs for the HPV FOCAL Study, a prospective investigation 
into the cost-effectiveness of utilizing the detection of HPV infection as a primary 
screening tool in B.C.
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objeCtives: Prolonged air leak (PAL) following lung resection results in increased 
length of stay (LOS), morbidity and costs. Pulmonary resection can be performed 
open or by video-assisted thoracic surgery (VATS). This study quantifies the total 
health care utilization and expenditures in patients who experienced a PAL after 
undergoing lung resection. Methods: This study utilized administrative health 
claims data from MarketScan® commercial and Medicare databases from 2009-
2011. Patients were included if they underwent a lobectomy, segmentectomy or 
wedge resection. Patients were classified as having a PAL if LOS was greater than 
5 days with a simultaneous ICD-9 code of 512.1 or 512.2 for pneumothorax. Data 
were analyzed on complications, LOS, readmission, and expenditures. Multivariable 
logistic regression analysis modeled for the binary outcome of PAL (yes or no). 
Expenditures and LOS were modeled using generalized linear models with a gamma 
distribution and log-link. Results: 27,366 records were analyzed, including 10,585 
lobectomies (39%), 2,100 segmentectomies (8%) and 14,681 wedge resections (53%). 
Multivariable logistic regression showed that open procedures are 40% (95% CI: 26% 
to 55%; p< 0.0001) more likely to suffer PALs than VATS. When PALs occur, open pro-
cedures are associated with longer LOS than VATS (12.2 versus 11.4 days; p= 0.0067) 
and are 75% (95% CI, 19% to 155%; p= 0.0040) more likely to get readmitted within 
30 days. Health care expenditures for patients with PALs are higher than for those 
without ($59,713 versus $44,077; p< 0.0001). ConClusions: PALs cause an eco-
nomic burden of ~$15,000 per patient in our health care system. VATS approach is 
associated with a significant reduction in PALs and total inpatient expenditures. 
In addition, when PALs occurred, VATS procedures were associated with a shorter 
LOS and reduced likelihood of readmission - thus reducing overall expenditure.
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objeCtives: Use of primary chemotherapy in the treatment of advanced ovarian 
cancer has increased in recent years. While, an on-going deliberation on the useful-
ness of this practice compared to primary debulking surgery (PDS) continues till 
date, none has studied monetary implications of the varying treatment practices. 
In this study, we estimate the lifetime costs of ovarian cancer by primary treat-
ment. Methods: A cohort of elderly women (≥ 65 years) with stage III and IV 
ovarian cancer was identified from the Surveillance, Epidemiology and End Results-
Medicare linked database from January 1, 2006- December 31, 2009. Cost analysis 
was conducted from a payer (i.e., Medicare) perspective, and direct medical costs 
incurred by Medicare were integrated for each patient. Cumulative treatment costs 
were estimated using phase of care approach (wherein the mean phase specific 
costs were weighted with the survival function), starting from date of diagnosis 
until death or last follow-up (December 2010). All costs were adjusted for geographic 
variation and inflation over time and discounted at a rate of 3%. Results: Among 
3408 patients, 17.3% (n= 591) received PDS, 57.2% (n= 1951) received primary chemo-
therapy (only 5.6% (n= 192) received subsequent surgery) and 25.4% (n= 866) did not 
receive either surgery or chemotherapy within 12 months of diagnosis. The mean 
lifetime costs in patients receiving no cancer directed treatment was $24,467; with 
the resultant incremental mean lifetime costs estimated as $37,434, $79,089 and 
$45,301 for patients receiving PDS, primary chemotherapy with subsequent surgery, 
and primary chemotherapy without surgery, respectively. ConClusions: The mean 
lifetime cost in patients receiving neoadjuvant chemotherapy followed by delayed 
debulking surgery is double the cost in those receiving PDS. In conjunction with 
